{"nctId":"NCT01636687","briefTitle":"Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)","startDateStruct":{"date":"2012-10-17","type":"ACTUAL"},"conditions":["Plaque-type Psoriasis"],"count":182,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Secukinumab 150 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Secukinumab 150mg"]},{"label":"Secukinumab 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Secukinumab 300mg"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Secukinumab 150mg","otherNames":[]},{"name":"Secukinumab 300mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Moderate and severe plaque-type psoriasis diagnosed for at least 6 months.\n* Severity of psoriasis disease meeting all of the following three criteria:\n\n  * Psoriasis Area and Severity Index (PASI) score of 12 or greater\n  * Investigator's Global Assessment (IGA) score of 3 or greater\n  * Total body surface area (BSA) affected of 10% or greater\n* Inadequate control by prior use of topical treatment, phototherapy and/or systemic therapy.\n\nExclusion criteria:\n\n* Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate).\n* Current drug-induced psoriasis.\n* Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.\n* Significant medical problems such as uncontrolled hypertension, congestive heart failure or a condition that significantly immunocompromises the subject.\n* Hematological abnormalities.\n* History of an ongoing, chronic or recurrent infectious disease, or evidence of untreated tuberculosis.\n* History of lymphoproliferative disease or history of malignancy of any organ system within the past 5 years.\n* Pregnant or nursing (lactating) women.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Psoriasis Area and Severity Index (PASI) 75 Response and Investigators' Global Assessment (IGA) Mod 2011 0 or 1 Response","description":"Efficacy of secukinumab compared to placebo in subjects with moderate to severe chronic plaque-type psoriasis.\n\nPASI score was based on assessment of the head, trunk, upper limbs and lower limbs for erythema, thickening (plaque elevation, induration), and scaling (desquamation). PASI scores can range from 0, corresponding to no signs of psoriasis, up to a theoretical maximum of 72.0. PASI-based secondary variables included absolute PASI score, response rates for PASI 75. PASI 50 and PASI 90 were defined as ≥ 50% and ≥ 90% improvement from Baseline in PASI score, respectively, while PASI 100 response corresponded to complete clearing of psoriasis (PASI = 0). IGA mod 2011 was used to evaluate the overall severity of psoriatic disease, with scores ranging from 0 (clear) to 4 (severe). Treatment success was defined as achievement of IGA mod 2011 0 or 1 score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.7","spread":null},{"groupId":"OG001","value":"86.7","spread":null},{"groupId":"OG002","value":"3.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.3","spread":null},{"groupId":"OG001","value":"73.3","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With Successful Self-administration of Study Drug at Week 1","description":"To assess the subject's ability to follow instructions for use with the secukinumab autoinjector","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Possible Use-related Hazards","description":"To assess potential use-related hazards with the secukinumab autoinjector for the subject.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5.1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.7","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Self-Injection Assessment Questionnaire (SIAQ) Domain Scores at Week 12","description":"The three domains of the POST SIAQ are feelings about injections, self-image, self-confidence, injection-site reactions, ease of use, and satisfaction with self-injection. The SIAQ items are scored on a semantic Likert-type scale where lower numbers indicate a worse experience. Domain scores range from 0 to 10; \"0\" corresponds to worst experience while \"10\" corresponds to best experience. Subjects self-injecting at this visit completed this SIAQ questionnaire. The POST-SIAQ is taken after the injection at that visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":"2.190"},{"groupId":"OG001","value":"1.13","spread":"1.796"},{"groupId":"OG002","value":"0.93","spread":"1.887"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.76","spread":"1.763"},{"groupId":"OG001","value":"1.68","spread":"1.901"},{"groupId":"OG002","value":"1.00","spread":"2.098"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.74","spread":"2.741"},{"groupId":"OG001","value":"2.63","spread":"2.361"},{"groupId":"OG002","value":"1.71","spread":"2.679"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Self-Injection Assessment Questionnaire (SIAQ) Domain Scores at Week 48","description":"The three domains of the POST SIAQ are feelings about injections, self-image, self-confidence, injection-site reactions, ease of use, and satisfaction with self-injection. The SIAQ items are scored on a semantic Likert-type scale where lower numbers indicate a worse experience. Domain scores range from 0 to 10; \"0\" corresponds to worst experience while \"10\" corresponds to best experience. Subjects self-injecting at this visit completed this SIAQ questionnaire. The POST-SIAQ is taken after the injection at that visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":"1.853"},{"groupId":"OG001","value":"1.34","spread":"2.336"},{"groupId":"OG002","value":"1.43","spread":"2.049"},{"groupId":"OG003","value":"0.73","spread":"1.450"},{"groupId":"OG004","value":"0.42","spread":"1.768"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.88","spread":"1.926"},{"groupId":"OG001","value":"1.86","spread":"2.052"},{"groupId":"OG002","value":"1.17","spread":"3.033"},{"groupId":"OG003","value":"1.70","spread":"2.145"},{"groupId":"OG004","value":"0.00","spread":"3.536"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.93","spread":"2.853"},{"groupId":"OG001","value":"2.50","spread":"2.121"},{"groupId":"OG002","value":"2.29","spread":"2.650"},{"groupId":"OG003","value":"1.98","spread":"2.853"},{"groupId":"OG004","value":"2.50","spread":"0.000"}]}]}]},{"type":"SECONDARY","title":"Percentages of Participants With PASI 50, PASI 75, PASI 90, PASI 100 and IGA Mod 2011 0 or 1 Response - Induction Period","description":"PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline.\n\nThe IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.3","spread":null},{"groupId":"OG001","value":"96.7","spread":null},{"groupId":"OG002","value":"8.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null},{"groupId":"OG001","value":"55.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"26.7","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Participants With PASI 50, PASI 75, PASI 90, PASI 100 and IGA Mod 2011 0 or 1 Response - Maintenance Period (Observed Data)","description":"PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline.\n\nThe IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.7","spread":null},{"groupId":"OG001","value":"70.7","spread":null},{"groupId":"OG002","value":"56.0","spread":null},{"groupId":"OG003","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.4","spread":null},{"groupId":"OG001","value":"82.8","spread":null},{"groupId":"OG002","value":"76.0","spread":null},{"groupId":"OG003","value":"96.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.1","spread":null},{"groupId":"OG001","value":"94.8","spread":null},{"groupId":"OG002","value":"88.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.7","spread":null},{"groupId":"OG001","value":"65.5","spread":null},{"groupId":"OG002","value":"52.0","spread":null},{"groupId":"OG003","value":"89.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.3","spread":null},{"groupId":"OG001","value":"39.7","spread":null},{"groupId":"OG002","value":"40.0","spread":null},{"groupId":"OG003","value":"64.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline for PASI Score - Induction Period","description":"PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\\* area score weight of section(head:01, arms:0.2 body:0.3 legs:0.4)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.52","spread":"7.841"},{"groupId":"OG001","value":"-16.67","spread":"6.552"},{"groupId":"OG002","value":"-1.26","spread":"6.621"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline for PASI Score Over Time up to Week 52 - Maintenance Period (Observed Data)","description":"Psoriasis Area and Severity Index (PASI): Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\\* area score weight of section(head:01, arms:0.2 body:0.3 legs:0.4).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.3","spread":"6.75"},{"groupId":"OG001","value":"-16.4","spread":"5.99"},{"groupId":"OG002","value":"-15.2","spread":"5.85"},{"groupId":"OG003","value":"-18.8","spread":"5.59"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Each IGA Mod 2011 Category - Induction Period","description":"The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":null},{"groupId":"OG001","value":"30.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":null},{"groupId":"OG001","value":"45.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"18.3","spread":null},{"groupId":"OG002","value":"8.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"6.7","spread":null},{"groupId":"OG002","value":"60.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"31.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Participants in Each IGA Mod 2011 Category Over Time up to Week 52 - Maintenance Period (Observed Data)","description":"The Investigators' Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.3","spread":null},{"groupId":"OG001","value":"39.7","spread":null},{"groupId":"OG002","value":"40.0","spread":null},{"groupId":"OG003","value":"64.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"31.0","spread":null},{"groupId":"OG002","value":"16.0","spread":null},{"groupId":"OG003","value":"21.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":null},{"groupId":"OG001","value":"19.0","spread":null},{"groupId":"OG002","value":"24.0","spread":null},{"groupId":"OG003","value":"10.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"6.9","spread":null},{"groupId":"OG002","value":"20.0","spread":null},{"groupId":"OG003","value":"3.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":null},{"groupId":"OG001","value":"3.4","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EQ-5D up to Week 12 - Induction Period","description":"ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example \"confined to bed\") A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":"19.63"},{"groupId":"OG001","value":"15.3","spread":"19.80"},{"groupId":"OG002","value":"-0.5","spread":"14.89"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EQ-5D Over Time up to Week 52 - Maintenance Period","description":"ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example \"confined to bed\") A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":"20.34"},{"groupId":"OG001","value":"17.4","spread":"20.38"},{"groupId":"OG002","value":"12.9","spread":"28.45"},{"groupId":"OG003","value":"9.9","spread":"10.94"},{"groupId":"OG004","value":"10.0","spread":"9.00"}]}]}]},{"type":"SECONDARY","title":"Percentage Changes From Baseline in Dermatology Life Quality Index (DLQI) Score - Induction Period","description":"The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). \"Not relevant\" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions.\n\nA negative median percent change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-83.3","spread":null},{"groupId":"OG001","value":"-86.8","spread":null},{"groupId":"OG002","value":"-17.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Changes From Baseline in Dermatology Life Quality Index (DLQI) Score Over Time up to Week 52 - Maintenance Period","description":"The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). \"Not relevant\" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions.\n\nA negative median percent change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-90.9","spread":null},{"groupId":"OG001","value":"-91.2","spread":null},{"groupId":"OG002","value":"-78.5","spread":null},{"groupId":"OG003","value":"-97.7","spread":null},{"groupId":"OG004","value":"-53.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 12 - Induction Period","description":"The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). \"Not relevant\" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.3","spread":null},{"groupId":"OG001","value":"74.6","spread":null},{"groupId":"OG002","value":"15.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Participants Achieving a DLQI Score of 0 or 1 Over Time up to Week 52 - (Maintenance)","description":"The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). \"Not relevant\" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.1","spread":null},{"groupId":"OG001","value":"70.0","spread":null},{"groupId":"OG002","value":"57.1","spread":null},{"groupId":"OG003","value":"85.7","spread":null},{"groupId":"OG004","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Participants With PASI 50, PASI 75, PASI 90, PASI 100 and IGA Mod 2011 0 or 1 Response After Week 52 (Observed Data)","description":"PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline.\n\nThe IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":null},{"groupId":"OG001","value":"58.3","spread":null},{"groupId":"OG002","value":"20.0","spread":null},{"groupId":"OG003","value":"73.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8","spread":null},{"groupId":"OG001","value":"87.5","spread":null},{"groupId":"OG002","value":"70.0","spread":null},{"groupId":"OG003","value":"86.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"70.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null},{"groupId":"OG001","value":"70.8","spread":null},{"groupId":"OG002","value":"40.0","spread":null},{"groupId":"OG003","value":"73.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"45.8","spread":null},{"groupId":"OG002","value":"20.0","spread":null},{"groupId":"OG003","value":"60.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline for PASI Score After Week 52 (Observed Data)","description":"PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\\* area score weight of section(head:01, arms:0.2 body:0.3 legs:0.4).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.7","spread":"5.66"},{"groupId":"OG001","value":"-15.9","spread":"4.58"},{"groupId":"OG002","value":"-12.7","spread":"8.08"},{"groupId":"OG003","value":"-18.1","spread":"5.49"}]}]}]},{"type":"SECONDARY","title":"Percentages of Participants in Each IGA Mod 2011 Category After Week 52 (Observed Data)","description":"The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"45.8","spread":null},{"groupId":"OG002","value":"20.0","spread":null},{"groupId":"OG003","value":"60.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":null},{"groupId":"OG001","value":"12.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"13.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"20.8","spread":null},{"groupId":"OG002","value":"50.0","spread":null},{"groupId":"OG003","value":"6.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"16.7","spread":null},{"groupId":"OG002","value":"20.0","spread":null},{"groupId":"OG003","value":"13.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"4.2","spread":null},{"groupId":"OG002","value":"10.0","spread":null},{"groupId":"OG003","value":"6.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Developing Treatment-emergent Anti-secukinumab Antibodies","description":"The development of anti-secunimubab anti-bodies decreases a participant's ability to respond to secukinumab treatment. The number of participants developing anti-secukinumab anti-bodies was measured from Baseline to week 216.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":61},"commonTop":["NASOPHARYNGITIS","HEADACHE","UPPER RESPIRATORY TRACT INFECTION","HYPERTENSION","BRONCHITIS"]}}}